What is the recommended management for overactive bladder in a female patient?

Management of Overactive Bladder in Female Patients

Start with behavioral therapy and oral pharmacotherapy (antimuscarinics or β3-adrenoceptor agonists), but you can offer minimally invasive therapies upfront if the patient prefers, without requiring trials of first-line treatments. 1

First-Line Treatment Approach

Initial Evaluation Requirements

• Perform urinalysis to exclude urinary tract infection or hematuria 2
• Measure post-void residual if considering botulinum toxin therapy later (use caution if PVR >100-200 mL) 1
• Consider bladder diary and symptom questionnaires for baseline assessment 1

Behavioral Modifications

Begin with lifestyle interventions including: 2

• Fluid intake optimization (avoid excessive or inadequate intake)
• Elimination of bladder irritants (caffeine, alcohol, acidic foods)
• Treatment of constipation
• Weight loss if overweight
• Timed voiding schedules
• Urge-suppression techniques
• Pelvic floor physical therapy

Second-Line Pharmacologic Management

Monotherapy Options

Choose either antimuscarinic agents or β3-adrenoceptor agonists: 3

• Antimuscarinics are more effective at reducing urgency urinary incontinence episodes but cause higher adverse events (dry mouth, constipation) 3
• β3-adrenoceptor agonists (mirabegron) are more effective at reducing nocturia episodes with better tolerability 3
• In patients over 65 years, mirabegron is increasingly preferred due to better safety profile 4

Combination Therapy for Refractory Cases

If monotherapy fails, add combination therapy with solifenacin 5 mg plus mirabegron 25-50 mg before escalating to third-line treatments. 1

• Combination therapy shows additive effect sizes (0.85-0.95) compared to monotherapy (0.36-0.56) for reducing micturition frequency 1
• Significantly superior for reducing urgency urinary incontinence, urgency episodes, and nocturia 1
• Slightly increased constipation and dry mouth compared to monotherapy, but generally well-tolerated 5

Third-Line Minimally Invasive Therapies

For patients with inadequate response to or intolerable side effects from pharmacotherapy, offer sacral neuromodulation, tibial nerve stimulation, or intradetrusor botulinum toxin injection. 1

Treatment Selection Algorithm

Intradetrusor OnabotulinumtoxinA (100 units): 1, 6

• Patient must be willing to perform clean intermittent self-catheterization if needed
• Measure PVR before injection; use caution if >100-200 mL 1
• Risk of urinary retention requiring catheterization is 6-8 times higher than placebo 3
• Risk of UTI is 2-3 times higher than placebo 3
• Reassess at 2 weeks post-injection for symptom improvement and check PVR to rule out retention 1
• More effective than antimuscarinics for cure of urgency urinary incontinence 3

Sacral Neuromodulation (SNM): 1, 3

• Success rate of 61% versus 42% with antimuscarinics 1
• Similar efficacy to botulinum toxin but with 9% device removal rate and 3% revision rate 3
• Lower recurrent UTI rate (10%) compared to botulinum toxin (24%) 3
• No requirement for self-catheterization

Percutaneous Tibial Nerve Stimulation (PTNS): 1

• Patient must be willing and able to make frequent office visits for repeated treatments 1
• Effective for reducing voiding frequency, nocturia, urgency, and incontinence episodes 1
• Main limitation is treatment burden of repeated in-office sessions 1

Key Clinical Pitfalls

• Do not require patients to fail all conservative therapies before offering minimally invasive options - shared decision-making allows direct access to third-line therapies based on patient preference 1
• Always measure PVR before botulinum toxin injection and counsel about catheterization risk 1
• Reassess patients 2 weeks after botulinum toxin to detect urinary retention early 1
• Consider urodynamic studies only for atypical symptoms or treatment failures, not for routine OAB diagnosis 1
• Avoid botulinum toxin in patients unwilling to self-catheterize as retention requiring catheterization occurs in significant proportion 3